Bruker Daltonics Announces July 11, 2003 Investor & Analyst Open House.Business Editors BILLERICA, Mass.--(BUSINESS WIRE)--June 9, 2003 Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL BDAL Battle Doll Angelic Layer (game) ) announces an open house event for investors and financial analysts at its headquarters at 40 Manning Road in Billerica on Friday, July 11, 2003. Assuming the announced merger with Bruker AXS closes on July 1st, 2003, as planned, management will outline its vision and plans for the combined Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. . The investor open house will start at 10 a.m. with management presentations, followed by Q&A. At 11:30 a.m., a facilities tour of the combined Bruker BioSciences headquarters and Bruker Daltonics customer demonstration/training, R&D and manufacturing facility will be offered. A light lunch will be served at 12 noon. Participants should RSVP (ReSerVation Protocol) A communications protocol that signals a router to reserve bandwidth for real time transmission. RSVP is designed to clear a path for audio and video traffic, eliminating annoying skips and hesitations. to Michael Willett. In view of the pending merger and joint S-4/A proxy statement/prospectus, the Company will not hold any investor activities at this week's American Society of Mass Spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. conference in Montreal. ABOUT BRUKER DALTONICS Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com. On April 4, 2003, Bruker Daltonics signed a definitive merger agreement with Bruker AXS Inc. (NASDAQ: BAXS). A joint S-4/A proxy statement/prospectus was filed with the SEC on May 19th, 2003. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion